Stocks › CC
Chemours Company (CC) stock analysis
SKIP 7% confidence · analysed Sep 10, 2026
This analysis is from Sep 10, 2026 and may be out of date.
On Sep 10, 2026, our model rated Chemours Company (CC) SKIP with 7% confidence at a price of $16.10. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 39. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (0.9x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $28.40 and the swing low is $10.29; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 1.60, which looks reasonably priced for its growth.
The company reports a profit margin of -5.2% and revenue growth of -1.5%.
In its latest quarter it earned $0.42 per share, which matched the $0.42 analysts expected, with revenue -1.5% year over year.
Wall Street's average rating is 2.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $19.00.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Research notes
Chemours (CC) still looks like a Hold on the latest public view, with analysts carrying an average price target around $20.10 versus the stock at about $15.58 on Sept. 8, implying upside if execution improves. The bull case is that Chemours is continuing its “Pathway to Thrive” execution program, which management says is aimed at strengthening the business mix and supporting future growth. The bear case remains weak operating momentum risk: the stock is still trading well below analyst targets, and recent coverage shows the market has not yet fully re-rated the story despite the strategy update. Price action and the latest public information are broadly consistent with your last neutral view: the stock is down about 2.7% from $15.04, and the current setup still looks more like a wait-and-see name than a clear bull or bear case.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.07 (SKIP). Technicals: RSI 38.76, MACD bullish, price below SMA50. Fundamentals: PEG 1.60, margin -5.2%, revenue growth -1.5%. Financial results: YoY revenue -1.5%, last EPS surprise +0.0%, next earnings 2026-11-05. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block. FinGPT news read: positive. Memory: 2 prior look(s); 50% of directional calls matched later price. Internet research: Chemours (CC) still looks like a **Hold** on the latest public view, with analysts carrying an average price target around **$20.10** versus the stock at about **$15.58** on Sept. 8, implying upside if execution improves. The bull case is that Chemours is continuing its “Pathway to Thrive” execution program, which management says is aimed at strengthening the business mix and supporting future growth. The bear case remains weak operating momentum risk: the stock is still trading well below analyst targets, and recent coverage shows the market has not yet fully re-rated the story despite the strategy update. Price action and the latest public information are broadly **consistent with your last neutral view**: the stock is down about **2.7%** from **$15.04**, and the current setup still looks more like a wait-and-see name than a clear bull or bear case. Reference price $15.22; no trade levels (SKIP).
Past ratings for CC
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 10, 2026 | SKIP | 7% | $16.10 | — | |
| Sep 9, 2026 | SKIP | 2% | $15.73 | +2.4% | |
| Sep 2, 2026 | SKIP | 11% | $15.53 | +3.7% | |
| Aug 21, 2026 | SKIP | 11% | $16.00 | +0.6% | |
| Aug 19, 2026 | WEAK SELL | 14% | $16.24 | -0.9% | ✔ right direction |
"Move since" compares each call's price with the latest analysed price.
Recent news on CC
- Oct 13, 2026: Barclays Initiates Coverage of Chemours at Equal-Weight (Nasdaq)
Other Basic Materials stocks we cover
CENX · CMP · DOW · DRD · ECVT · FUL · GFI · HL · LIN · MATV · NTR · NUE
Frequently asked questions
Is CC a buy right now?
As of Sep 10, 2026, our automated model rates Chemours Company (CC) SKIP with 7% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Chemours Company report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.